Selvita Valuation

Q: What is the Fair Price of SLV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SLV (PLN53.5) is trading below our estimate of [[fair value]] (PLN93.42)

Is SLV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SLV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SLV (PLN53.5) is trading below our estimate of fair value (PLN93.42)

Significantly Below Fair Value: SLV is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SLV?

Key metric: As SLV is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SLV. This is calculated by dividing SLV's market cap by their current earnings.
What is SLV's PE Ratio?
PE Ratio	20.7x
Earnings	zł47.40m
Market Cap	zł982.02m

SLV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.6x
Enterprise Value/EBITDA	52.4x
PEG Ratio	1.4x

Price to Earnings Ratio vs Peers

How does SLV's PE Ratio compare to its peers?

The above table shows the PE ratio for SLV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	60.6x
SVE Synthaverse	125x	n/a	zł309.2m
FF Fine Foods & Pharmaceuticals N.T.M	40.9x	30.7%	€198.3m
524394 Vimta Labs	35.2x	n/a	₹17.4b
LFCR Lifecore Biomedical	41.5x	-40.1%	US$235.7m
SLV Selvita	20.7x	15.0%	zł982.0m

Price-To-Earnings vs Peers: SLV is good value based on its Price-To-Earnings Ratio (20.7x) compared to the peer average (60.6x).

Price to Earnings Ratio vs Industry

How does SLV's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: SLV is good value based on its Price-To-Earnings Ratio (20.7x) compared to the European Life Sciences industry average (37.1x).

Price to Earnings Ratio vs Fair Ratio

What is SLV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SLV PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	20.7x
Fair PE Ratio	61.6x

Price-To-Earnings vs Fair Ratio: SLV is good value based on its Price-To-Earnings Ratio (20.7x) compared to the estimated Fair Price-To-Earnings Ratio (61.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SLV forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	zł53.50	zł69.23 +29.4%	11.1%	zł78.70	zł58.00	n/a	6
Nov ’25	zł53.70	zł69.23 +28.9%	11.1%	zł78.70	zł58.00	n/a	6
Oct ’25	zł57.50	zł69.65 +21.1%	10.4%	zł78.70	zł58.00	n/a	6
Sep ’25	zł67.00	zł70.98 +5.9%	7.7%	zł78.70	zł62.70	n/a	6
Aug ’25	zł68.90	zł70.98 +3.0%	7.7%	zł78.70	zł62.70	n/a	6
Jul ’25	zł67.70	zł70.98 +4.8%	7.7%	zł78.70	zł62.70	n/a	6
Jun ’25	zł66.00	zł70.98 +7.6%	7.7%	zł78.70	zł62.70	n/a	6
May ’25	zł69.60	zł68.98 -0.9%	8.5%	zł78.70	zł62.70	n/a	5
Apr ’25	zł66.70	zł71.58 +7.3%	7.3%	zł78.70	zł65.00	n/a	5
Mar ’25	zł59.00	zł70.18 +18.9%	10.5%	zł78.70	zł58.00	n/a	5
Feb ’25	zł59.20	zł70.18 +18.5%	10.5%	zł78.70	zł58.00	n/a	5
Jan ’25	zł58.50	zł77.94 +33.2%	26.5%	zł117.50	zł58.00	n/a	5
Dec ’24	zł63.00	zł77.94 +23.7%	26.5%	zł117.50	zł58.00	n/a	5
Nov ’24	zł62.70	zł81.74 +30.4%	22.3%	zł117.50	zł66.00	zł53.70	5
Oct ’24	zł62.50	zł84.70 +35.5%	20.5%	zł117.50	zł66.00	zł57.50	5
Sep ’24	zł67.20	zł84.90 +26.3%	20.2%	zł117.50	zł67.00	zł67.00	5
Aug ’24	zł74.40	zł84.90 +14.1%	20.2%	zł117.50	zł67.00	zł68.90	5
Jul ’24	zł67.90	zł84.90 +25.0%	20.2%	zł117.50	zł67.00	zł67.70	5
Jun ’24	zł68.50	zł86.10 +25.7%	18.6%	zł117.50	zł73.00	zł66.00	5
May ’24	zł75.00	zł86.10 +14.8%	18.6%	zł117.50	zł73.00	zł69.60	5
Apr ’24	zł75.00	zł93.94 +25.3%	17.7%	zł117.50	zł73.00	zł66.70	5
Mar ’24	zł80.90	zł96.34 +19.1%	14.7%	zł117.50	zł77.00	zł59.00	5
Feb ’24	zł84.90	zł90.84 +7.0%	10.3%	zł102.20	zł77.00	zł59.20	5
Jan ’24	zł82.90	zł90.84 +9.6%	10.3%	zł102.20	zł77.00	zł58.50	5
Dec ’23	zł80.80	zł90.84 +12.4%	10.3%	zł102.20	zł77.00	zł63.00	5
Nov ’23	zł84.50	zł90.64 +7.3%	10.5%	zł102.20	zł77.00	zł62.70	5

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.